Poxel Presents New Data on Imeglimin and PXL770 at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases in Los Angeles Nov 23, 2015
Imeglimin’s Innovative Mitochondria-Targeted Mechanism of Action Recognized by the Scientific Committee of the World Mitochondria Society Nov 2, 2015
Unique Mitochondria-targeting Mechanism of Action Confirmed for Poxel’s Oral Agent Imeglimin Oct 30, 2015
Poxel Reports Cash Position, Financial Results for the Third Quarter 2015 and Provides Corporate Update Oct 22, 2015
Poxel Announces Upcoming Presentations on New Imeglimin Data at Two Key Scientific Conferences Oct 7, 2015
POXEL Raises EUR 20 Million in a Private Placement Led by Leading US Healthcare Investors Jul 24, 2015
Poxel’s Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial Jun 6, 2015
